In the Journals

Switching from Remicade to biosimilar Inflectra safe, effective through 1 year in IBD

December 7, 2017
Patients with inflammatory bowel disease who switched from Remicade to Inflectra showed no differences in drug levels or disease activity through 1…
FDA News

FDA approves Ogivri, first biosimilar for certain breast, stomach cancers

December 1, 2017
The FDA today approved trastuzumab-dkst, the first biosimilar to treat patients with breast cancer or gastric or gastroesophageal junction…
Meeting News

Remicade biosimilar Inflectra shows safety, efficacy through 1 year in IBD

November 3, 2017
Patients with inflammatory bowel disease who switched from Remicade to its biosimilar Inflectra — marketed as Remsima in the U.K. — or…

Biosimilars may reduce US health care spending by $54 billion

October 23, 2017
A study recently published by the RAND Corporation showed biosimilars may lead to a reduction in health care spending in the United States on…

Multidisciplinary task force releases consensus document on biosimilars

October 2, 2017
While several national and international medical subspecialty organizations have demonstrated conflicting views on the use of biosimilars for…

WHO creates pilot program to use biosimilars to address ‘prohibitively expensive’ cancer drugs

September 28, 2017
The WHO has launched a pilot project to encourage the development of biosimilar versions of rituximab and trastuzumab – two products on the WHO…

Amgen to collaborate with Simcere to co-develop, commercialize biosimilars in China

September 27, 2017
Amgen and Simcere Pharmaceutical Group announced a collaboration to co-develop and commercialize four biosimilars in China. The deal includes…

Expert panel discusses concerns, opportunities surrounding biosimilars in the US

September 27, 2017
Biosimilars remain an unfamiliar and oftentimes controversial topic among physicians in the U.S. Unanswered questions surrounding both the scientific…

Pfizer files suit claiming Johnson & Johnson stifles biosimilar competition

September 21, 2017
Pfizer, the manufacturer of Inflectra, a biosimilar to Janssen’s Remicade, filed a lawsuit against Johnson & Johnson, the parent company of…

Samsung Bioepis receives positive opinion for Herceptin biosimilar

September 18, 2017
Samsung Bioepis received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for Ontruzant